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Abstract
Rationale: Persistent tachypnea of infancy (PTI) is a speciﬁc clinical
entity ofundeﬁnedetiology comprising the twodiseasesneuroendocrine
cell hyperplasia of infancy (NEHI) and pulmonary interstitial
glycogenosis. The outcome of typical NEHI is favorable. The outcome
may be different for patients without a typical NEHI presentation, and
thus a lung biopsy to differentiate the diseases is indicated.
Objectives: To determine whether infants with the characteristic
clinical presentation and computed tomographic (CT) imaging of
NEHI (referred to as “usual PTI”) have long-term outcome and
biopsy ﬁndings similar to those of infants with an aberrant
presentation and/or with additional localized minor CT ﬁndings
(referred to as “aberrant PTI”).
Methods: In a retrospective cohort study, 89 infants with PTI were
diagnosed on the basis of clinical symptoms and, if available, CT
scans and lung biopsies. Long-term outcome in childhood was
measured on the basis of current status.
Measurements and Main Results: Infants with usual
PTI had the same respiratory and overall outcomes during
follow-up of up to 12 years (mean, 3.8 yr) as infants who
had some additional localized minor ﬁndings (aberrant
PTI) visualized on CT images. Both usual and aberrant
PTI had a relatively favorable prognosis, with 50% of
the subjects fully recovered by age 2.6 years. None of
the infants died during the study period. This was
independent of the presence or absence of histological
examination.
Conclusions: PTI can be diagnosed on the basis of typical history
taking, clinical ﬁndings, and a high-quality CT scan. Further
diagnostic measures, including lung biopsies, may be limited to rare,
complicated cases, reducing the need for an invasive and potentially
harmful procedure.
Keywords: children’s interstitial lung disease; diffuse parenchymal
lung disease; infants; neuroendocrine cell hyperplasia of infancy;
pulmonary interstitial glycogenosis
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Diffuse lung diseases in children comprise a
heterogeneous group of rare pediatric
disorders (1). The current categorization
system lists four groups as more prevalent
among infants than in other life stages:
diffuse developmental disorders of the
lungs, abnormalities of alveolar growth,
disorders related to surfactant dysfunction,
and a group called “speciﬁc conditions of
undeﬁned etiology” (2). The last group
comprises two diseases: neuroendocrine cell
hyperplasia of infancy (NEHI) (3) and
pulmonary interstitial glycogenosis
(PIG) (2).
NEHI presents in infants similarly to an
interstitial lung disease, with symptoms of
tachypnea, hypoxemia, crackles, retractions,
and failure to thrive (3–9). Initially, the
condition was labeled “persistent tachypnea
of infancy” (PTI) (5) or “chronic idiopathic
bronchiolitis of infancy” (9). The histology
of NEHI is mostly normal or has minor
abnormalities (8, 9). Because this condition
is associated with increased numbers of
neuroendocrine cells (NECs) (3), lung
biopsies became an important diagnostic
procedure. However, it soon became clear
that hyperplasia of those cells was not a
speciﬁc feature of NEHI (i.e., PTI), as this
presentation has been described in a variety
of other rare pediatric lung diseases (3, 10).
Within the ﬁrst months of life, PIG
presents with rapid and difﬁcult breathing
and hypoxemia (11). Histological
examinations show oval, glycogen-rich
mesenchymal cells expanding the
interstitium. No ﬁbrosis or inﬂammatory
reaction is seen (11–20). Of interest, NECs
are also hyperplastic (10).
The prognosis of infants categorized as
having speciﬁc conditions of undeﬁned
etiology is commonly considered favorable,
making it difﬁcult to argue for open lung
biopsy to conﬁrm the diagnosis. Therefore,
chest imaging has been of major interest for
diagnosis because most patients with NEHI
have typical computed tomographic (CT)
ﬁndings with ground-glass opacities
conﬁned to the middle lobe, lingula, and
paramediastinal lung areas. Some patients,
however, have additional CT abnormalities,
such as consolidation, bronchial wall
thickening, and interlobular septal
thickening. Sometimes ground-glass
opacities are absent or have a different
distribution (3, 6, 7, 21). With regard to
biopsy-proven PIG, the few published CT
studies have shown mainly ground-glass
opacities in a subsegmental, segmental, or
diffuse distribution (11, 15), very similar to
what was found in NEHI (11): interlobar
septal thickening or scarring,
hyperinﬂation, air trapping, multifocal
atelectasis (7), and multiple air-ﬁlled cystic
changes of variable size (12).
Thus, relevant questions arise
regarding whether infants with the
characteristic presentation of PTI and
atypical CT imaging have the same biopsy
ﬁndings and, more important, have the
same long-term outcomes as infants with
PTI with typical CT imaging ﬁndings. If that
is the case, lung biopsies will be needed only
for severe cases with uncertain diagnosis,
reducing the need for an invasive and
potentially harmful procedure.
Methods
Study Cohort
The Kids Lung Register collects cases of rare
pediatric lung diseases, with a focus on
diffuse lung diseases (www.kids-lung-
register.eu) (22). For all children included
in the present study, underlying immune
deﬁciency, cystic ﬁbrosis, primary ciliary
dyskinesia, infections, and congenital heart
disease were ruled out. The diagnosis of
diffuse parenchymal lung disease (DPLD)
was made in accordance with the clinical
guidelines of the American Thoracic
Society (1). All patients included had
clinical DPLD deﬁned by (1) typical
symptoms or signs such as tachypnea
and/or dyspnea, crackles, retractions, digital
clubbing, failure to thrive, or respiratory
failure; (2) hypoxemia; and (3) diffuse
radiological abnormalities present at
diagnosis with a minimum duration of
4 weeks. The children were categorized
into the distinct DPLD categories and
subcategories (22). Between 2001 and 2015,
89 children were allocated to a group
referred to as “infant persistent tachypnea
of unknown etiology,” which is the same as
speciﬁc conditions of undeﬁned etiology.
Allocation was based on the presence of
persistent tachypnea; CT changes with
mainly ground-glass opacities and only
minor other abnormalities; and exclusion of
diffuse developmental disorders, deﬁcient
alveolarization, surfactant dysfunction
disorders, or other conditions that occur in
all age groups (see Methods section in the
online supplement).
Retrospective information from patient
ﬁles was collected on breathing frequency,
crackles, retractions and/or dyspnea, failure
to thrive, chest wall abnormalities such as
pectus excavatum noted on CT scans,
desaturation or respiratory insufﬁciency,
and age at onset of symptoms. PTI was
diagnosed if there was an increased
respiratory rate at the onset of symptoms or
at the time of diagnosis and documented
in medical ﬁles during infancy on at least
two additional occasions more than 3 weeks
apart and persisting within that period
based on the judgment of subjects’
caregivers. Age-matched normal
respiratory rates were taken from the
percentile curves reported by Fleming and
coworkers (23). The age at the end of
tachypnea and the last follow-up status
were obtained cross-sectionally in 2015 by
structured telephone contact with
caregivers of the children or with the
children’s treating physicians.
Radiological Characterization
Chest CT scans were systematically
reevaluated using a scoring system based on
the results of a previous CT study to allow
comparisons with other studies using the
same instruments (7). Ground-glass
opacities were regarded as typical when
At a Glance Commentary
Scientiﬁc Knowledge on the
Subject: Persistent tachypnea of
infancy is a characteristic but
frequently undiagnosed chronic lung
disorder. A deﬁnitive diagnosis and
precise categorization as either
neuroendocrine cell hyperplasia of
infancy or pulmonary interstitial
glycogenosis can be achieved only by
lung biopsy. There is uncertainty
regarding the long-term outcome of a
larger cohort of these conditions and
about the necessity and value of a lung
biopsy for their diagnosis.
What This Study Adds to the
Field: Infants with persistent
tachypnea and characteristic ground-
glass opacities (usual) and with some
additional local and minor ﬁndings
(aberrant) visualized by computed
tomography had the same favorable
respiratory and overall outcomes. Lung
biopsies may be useful only in rare,
complicated cases.
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they were located in the middle lobe,
the lingula, and the parahilar and
paramediastinal distributions
(i.e., centrally) (6). Ground-glass opacities
in other distributions were considered
atypical. Similarly, ground-glass opacities
were judged as atypical when they were
demonstrated on expiratory images only,
irrespective of location. All additional
ﬁndings on CT images, including bronchial
wall thickening, architectural distortion,
pleural effusion, interlobular thickening,
focal consolidation (excluding dependent
atelectasis), parenchymal cysts,
bronchiectasis, and honeycombing, were
considered atypical. Because of an
insufﬁcient number of expiratory scans (27
of 77 CT scans), air trapping could not be
investigated systemically. All infants with
PTI and typical CT ﬁndings were
categorized as having usual PTI, and those
with atypical CT ﬁndings were classiﬁed as
having aberrant PTI.
Lung Biopsies and
Immunohistochemistry
The presence of NECs was determined by
immunohistochemistry for bombesin,
chromogranin A, and synaptophysin in
consecutive formalin-ﬁxed, parafﬁn-
embedded sections.
All tissue sections were counted, and
quantiﬁcation was performed with the
observer blinded to case or control status
and reviewed independently by another
board-certiﬁed pathologist (S.R.). For each
tissue section, the number of bronchioles,
the number of immunopositive NECs, and
the number of bronchiolar epithelial cells
were counted manually. The number of
immunostained NECs was expressed as a
percentage of the total epithelial cells of
the bronchiole. The number of bronchioles
with immunostained NECs was expressed
as a percentage and total number. All
bronchioles with at least 10% NECs were
counted and expressed as a total number.
Statistical Analysis
Patient and control groups for histology
were compared using two-way analysis of
variance with the Bonferroni post hoc test.
Clinical parameters and staining results
were compared using Kruskal–Wallis
analysis of variance with Dunn’s post hoc
test or Fisher’s exact test. Survival analyses
were performed using a log-rank
(Mantel–Cox) test. For all analyses, P<
0.05 was considered statistically signiﬁcant.
Ethics Statement
All participants or their parents provided
written informed consent to participate in
the Kids Lung Register consultation and
diagnosis program. The Ethics Commission
at the Ludwig Maximilians University of
Munich approved the study (EK 026-06,
257-10, 111-13).
Results
Study Population
Between 2001 and 2015, 1,105 children with
suspected DPLD were included in the Kids
Lung Register. Among them, 89 were
categorized as having speciﬁc conditions of
undeﬁned etiology or infant persistent
tachypnea of unknown etiology (Figure 1).
Chest CT scans obtained at diagnosis were
retrieved for 80 of these infants with chronic
tachypnea at the onset of their pulmonary
symptoms. The infants were grouped as
having usual PTI based on the presence of
ground-glass opacities in typical locations
(middle lobe, lingula, paramediastinal, and/or
parahilar) or as having no other abnormalities
(usual PTI) or aberrant PTI if ground-glass
opacities were present in atypical locations
and/or if additional abnormalities were
observed (aberrant PTI) (Figure 1). Lung
biopsies with immunohistochemical staining
were performed in 20 of the subjects with
usual PTI and 13 of the subjects with aberrant
PTI (Figure 1).
Clinical Characteristics
Infants with usual PTI were older at the
onset of any symptoms than infants with
aberrant PTI (3.5 mo vs. 1.3 mo) (P, 0.001)
(Table 1, Figure 2A). Most of the subjects in
both groups presented at symptom onset
with retractions, hypoxemia, and a need
for oxygen (Table 1; see also Figure E1
in the online supplement). A few
subjects presented with chest wall
abnormalities such as pectus excavatum.
Crackles occurred more often in infants in
the usual PTI group than in infants in the
aberrant PTI group (P, 0.01). Also, more
subjects with usual PTI had failure to thrive
(P, 0.05).
During the disease course, about 10% of
infants in both groups were exposed to
passive smoking. Asthma was diagnosed in
6% of the usual PTI group and 20% of the
aberrant PTI group, but this association was
not signiﬁcant. About one-third of the
subjects presented with other
nonrespiratory diseases (Table 1).
Additionally, half of the subjects in both
groups had a history of upper and lower
respiratory tract infections and pneumonia.
The mean ages of the subjects at last
follow-up were 4.2 years in the usual PTI
group and 3.2 years in the aberrant PTI
category. The oldest age at last follow-up
was 10.5 years in the usual PTI category and
12.0 years in the aberrant PTI group. More
than 80% of the children in both groups
were healthy or had symptoms that had
weakened in intensity and/or number
(“sick—better”) at last follow-up, and only
two patients with usual PTI and six patients
with aberrant PTI still had the same
symptoms with the same intensity and
number (“sick—same”) at their last follow-
up. None of the children had a higher
number of symptoms and/or more intense
symptoms (“sick—worse”), and none had
died (Table 1). Most of the children had
improved or become asymptomatic
(“healthy”); in both of these groups, 50%
had become healthy by age 2.6 years
(Figures 2B and 2C). There were no
differences in the duration of oxygen
therapy or the ﬂow of oxygen delivered
(Table 1, Figure E1).
Considering the tachypnea symptom
alone, 34.8% of the patients with usual PTI
and 53.6% of the patients with aberrant PTI
were still tachypneic at last follow-up
(Table 1). The time course of normalization
of respiratory rate was initially the same, as
50% of all subjects had overcome their
tachypnea by age 2.6 years (Figure 2D).
However, tachypnea tended to persist
longer in subjects with aberrant PTI
(P = 0.179). The mean ages at the end of
tachypnea were 2.4 years in the usual PTI
group and 3.7 years in the aberrant PTI
group (not signiﬁcant) (Table 1).
Many but not all of the respiratory
rates measured and documented by
physicians at the onset of disease were above
the 99th percentile. During observation,
respiratory rates decreased but in many
cases were above the 50th percentile
(see Figure E2).
Radiological Characteristics
Among 80 subjects, according to their CT
scans, 50 had usual PTI and the other 30
were classiﬁed as having aberrant PTI. Of
the 30 subjects with aberrant PTI, 14 had
ground-glass opacities in other locations
and/or other signiﬁcant abnormalities, such
as focal consolidation, parenchymal cysts,
ORIGINAL ARTICLE
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pleural effusion, architectural distortion,
interlobular septal thickening, and bronchial
wall thickening (Table 2). Ground-glass
opacities were seen on expiratory images
only, in two subjects. After separating the
two PTI groups into those with and those
without biopsies, no differences in CT
ﬁndings were identiﬁed.
Histopathology
Not considering special stains for NECs, we
observed that lung biopsy samples were
normal or had only minor abnormalities
(see Table E1). We found that 4 of 20
samples from subjects with usual PTI and 1
of 13 samples from those with aberrant PTI
looked completely normal. There were no
differences between groups. In a few
samples, discrete chronic bronchiolitis or
lymphocytic inﬂammation of airways was
noted. Some subjects had mild to moderate
alveolar septal thickening or intraalveolar
macrophage accumulation. In four subjects,
the most prominent ﬁndings were round,
glycogen-rich mesenchymal cells that
Kids Lung Register (KLR) 2001–2015
All cases of the category: “Specific conditions of undefined etiology”
(A3, Infant chronic tachypnea of unknown etiology)
(n = 89)
Infants with persistent tachypnea and CT scan with mainly
ground-glass opacities or only minor abnormalities
Patient has CT scan which may have ground-
glass opacities confined to middle lobe,
lingula, parahilar, and paramediastinal
areas; additional lobes may be involved and
other abnormalities may be present.
(n = 30)
Patient has CT scan at diagnosis with
ground-glass opacities confined
to middle lobe,
lingula, parahilar, and paramediastinal
areas, no additional abnormalities.
(n = 50)
Aberrant persistent tachypnea of infancy
(aberrant PTI)
Usual persistent tachypnea of infancy
(usual PTI)
Lung biopsy Yes (n = 20) No (n = 30) Yes (n = 13) No (n = 17)
No CT scan available for this study
(n = 9)
CT scan available for this study
(n = 80)
Neuroendocrine cell hyperplasia of infancy (NEHI)*n = 14 n = 7
Pulmonary interstitial glycogenosis (PIG)**n = 0 n = 4
Normal lung tissue***n = 6 n = 2
Figure 1. Subject allocation flow. *Neuroendocrine cell hyperplasia of infancy is hyperplasia of neuroendocrine cells (NECs) in lung tissue, defined as
immunopositive NECs in more than 70% of bronchioles and at least 10% NECs in at least one bronchiole. **Pulmonary interstitial glycogenosis is periodic
acid–Schiff stain–positive glycogen with thickening of alveolar septa. ***Normal lung tissue is no hyperplasia of NECs in lung tissue. CT = computed
tomography; PTI = persistent tachypnea of infancy.
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widened the interstitial walls, which was
conﬁrmed by periodic acid–Schiff stain and
provided the basis for the diagnosis of PIG.
Immunohistochemistry
In the control group with healthy tissue, the
maximum frequency distribution of NECs
and/or bronchiolar cells (expressed as a
percentage) was in the range of 1.00–2.99%
based on bombesin staining, whereas the
maximum for chromogranin and
synaptophysin staining was in the range of
0.00–0.99% (Figures 3A–3C; see also Table
E2). NEHI was previously deﬁned by
immunopositive NECs in more than 70% of
all bronchioles and at least 10% NECs in at
least one bronchiole (8). The ﬁrst part of
this deﬁnition was not very speciﬁc in our
hands, as in the healthy control group
bombesin and chromogranin stains showed
more than 70% immunopositive NECs (see
Figure E3D), demonstrating signiﬁcant
overlap. The second part was suitable in our
cohort, as none of the control subjects had
bronchioles with at least 10% NECs of total
bronchiolar cells (see Figure E3C).
Among the 20 subjects with usual PTI,
14 had bronchioles with at least 10% NECs
among total bronchiolar cells and were
conﬁrmed as having a histological NEHI,
Table 1. Clinical Characterization and Outcomes of Children with Persistent Tachypnea of Infancy
Usual PTI Aberrant PTI
All (n = 50)
With Biopsy
(n = 20)
Without Biopsy
(n = 30) All (n = 30)
With Biopsy
(n = 13)
Without Biopsy
(n = 17)
At onset of any symptoms
Age, mo 3.5 (0–20)* 3.9 (0–20) 3.3 (0–11) 1.3 (0–10)* 0.4 (0–3) 1.9 (0–10)
Tachypnea 50 (100) 20 (100) 30 (100) 30 (100) 13 (100) 17 (100)
Crackles 43 (86.0)† 18 (90.0) 25 (83.3) 16 (53.3)† 7 (53.8) 9 (52.9)
Retractions 41 (82.0) 14 (70.0) 27 (90.0) 26 (86.7) 11 (84.6) 15 (88.2)
Failure to thrive 31 (65.9)‡ 14 (73.7) 17 (58.6) 10 (41.7)‡ 6 (75.0) 4 (25.0)
Chest wall abnormalities 11 (22.0) 6 (30.0) 5 (16.7) 3 (10.0) 2 (15.4) 1 (5.9)
Hypoxemia, desaturation
(respiratory insufﬁciency)
44 (88.0) 16 (80.0) 28 (93.3) 22 (73.3) 11 (84.6) 11 (64.7)
Oxygen supplementation 39 (78.0) 14 (70.0) 25 (83.3) 21 (70.0) 11 (84.6) 10 (58.8)
Fever 7 (14.0) 3 (15.0) 4 (13.3) 1 (3.3) 0 (0) 1 (5.8)
Preterm birth 1 (2.8) 0 (0) 1 (4.0) 4 (15.4) 2 (22.2) 2 (11.8)
At biopsy
Age, yr 1.2 (0.3–4.4) 1.2 (0.3–4.4) — 1.1 (0.2–4.3) 1.1 (0.2–4.3) —
At end of tachypnea
Age, yr 2.4 (0.7–4.6) 2.7 (0.7–4.6) 2.2 (0.8–3.2) 3.7 (0.3–10.6) 4.5 (2.0–8.2) 3.0 (0.3–10.6)
Until last follow-up
Passive smoking 2 (10.5) 0 (0) 2 (20.0) 1 (10.0) 0 (0) 1 (14.3)
Lowest oxygen
saturation, %
87.4
(74.0–100.0)
87.8
(80.0–100.0)
87.2
(74.0–97.0)
87.5
(69.0–100.0)
83.9
(70.0–93.0)
90.1
(69.0–100.0)
Duration of oxygen therapy, yr 1.5 (0–5.3) 1.8 (0–5.3) 1.3 (0–4.8) 1.0 (0–3.7) 1.4 (0–3.7) 0.7 (0–2.6)
Nasal oxygen ﬂow, L/min 0.8 (0.3–2.0) 0.7 (0.3–1.1) 0.8 (0.4–2.0) 1.4 (0.1–2.3) 1.4 (0.7–2.3) 1.5 (0.1–2.3)
Physician-diagnosed asthma 3 (6.0) 0 (0) 3 (10.0) 6 (20.0) 2 (15.4) 4 (23.5)
Other nonrespiratory diseases 15 (30.0) 8 (40.0)x 7 (23.3)x 16 (43.3) 8 (61.5)x 5 (29.4)x
Upper respiratory tract infections 24 (48.0) 7 (35.0) 17 (56.7) 12 (42.9) 4 (36.4) 8 (47.1)
Lower respiratory tract infections 34 (68.0) 14 (70.0) 20 (66.7) 15 (53.6) 7 (63.6) 8 (47.1)
History of pneumonia 23 (46.0) 10 (50.0) 13 (43.3) 12 (42.9) 5 (45.5) 7 (41.2)
At last follow-up
Age, yr 4.2 (0.7–10.5) 4.5 (0.8–10.5) 4.0 (0.7–8.3) 3.2 (0.3–12.0) 3.6 (0.3–12.0) 2.9 (0.3–11.3)
Health status
Healthy 25 (50.0) 11 (55.0) 14 (46.7) 11 (36.7) 2 (15.4) 8 (47.1)
Sick—better║ 23 (46.0) 8 (40.0) 15 (50.0) 13 (43.3) 8 (61.5) 6 (35.3)
Sick—same¶ 2 (4.0) 1 (5.0) 1 (3.3) 6 (20.0) 3 (23.1) 3 (17.6)
Physician-reported tachypnea 16 (34.8) 5 (29.4) 11 (37.9) 15 (53.6) 7 (63.6) 8 (47.1)
Failure to thrive 3 (6.1) 0 (0) 3 (10.3) 3 (10.7) 2 (18.1) 1 (5.9)
Definition of abbreviation: PTI = persistent tachypnea of infancy.
Data are presented as mean (range) or number of cases (%). Statistical comparisons were made between usual PTI, all, and aberrant PTI, all. Other
parameters were not significantly different between usual PTI, all, and aberrant PTI, all. No differences with or without biopsy within a PTI group were found
(Fisher’s exact test, Mann–Whitney U test).
*P, 0.001 (Mann–Whitney U test).
†P, 0.01 (Fisher’s exact test).
‡P, 0.05 (Fisher’s exact test).
xGastroesophageal reflux disease, Beckwith-Wiedemann syndrome, muscular hypotonia, developmental disorder, myocardiopathy, iron deficiency anemia,
strabismus, Langerhans cell histiocytosis, hearing impairment, hypermobility syndrome, atopic dermatitis, tubular proteinuria, inguinal hernia, Hunter
syndrome, ventricular septal defect, hypoxic ischemic encephalopathy, autism, Gilbert–Meulengracht syndrome, hydronephrosis, pharyngomalacia,
multicystic dysplastic kidney.
║“Sick—better” is defined as signs and symptoms of the disease having weakened in intensity and/or number.
¶“Sick—same” is defined as same signs and symptoms with same intensity and number.
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whereas the other 6 subjects were not
(Figure 1).
Among the 13 subjects with aberrant
PTI, 11 had NEC hyperplasia and 2 did not.
Four of the subjects with NEC hyperplasia
also had thickening of alveolar septa and
increased periodic acid–Schiff–positive
mesenchymal cells and were consequently
characterized as having PIG (Figure 1).
Only in bombesin staining was the
number of bronchioles with more than 10%
NECs among total bronchiolar cells
signiﬁcantly higher in the usual PTI group
(P, 0.01) and the aberrant PTI group
(P, 0.001) (see Figure E3B and Table E2).
There was no signiﬁcant difference between
the control group and the patient groups in
chromogranin or synaptophysin staining.
The mean number of NECs among
bronchiolar cells (as a percentage) and the
mean percentage of bronchioles with at least
10% NECs among bronchiolar cells were
highest on bombesin stains, and bombesin
was superior to chromogranin and
synaptophysin staining. No signiﬁcant
differences were observed between the usual
PTI and aberrant PTI groups in any staining
(see Figure E3 and Table E2).
Bombesin in Urine
The urine concentration of bombesin and
the ratio of bombesin to creatinine did not
differ between control subjects, subjects with
usual PTI, and subjects with aberrant PTI
(see Figure E4 and Table E3).
Discussion
Our longitudinal study shows that
respiratory and overall outcomes of more
than 80 infants with PTI were not
dependent on CT imaging or lung biopsy
ﬁndings. Importantly, outcomes were rather
favorable, improving over time, and no
deaths were observed, conﬁrming a previous
small set of long-term data (4).
Two strengths of the study were the
detailed clinical characterization of the
infants and the correlation to the other
variables. Comprehensive analysis of the CT
scans clearly showed two types of ﬁndings.
On the one hand, CT scans with ground-
glass opacities were located only in the
middle lobe, the lingula, and the parahilar
and paramediastinal distributions. This
pattern was described earlier as being typical
of NEHI (7) and in our study was deﬁned as
infants with usual PTI. On the other hand,
infants were classiﬁed as having aberrant
PTI when the ground-glass opacities were
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in nontypical locations and/or when
additional abnormalities or, rarely, no
abnormalities were detected.
Whereas the usual and aberrant groups
were similar in most clinical signs and
symptoms, and in particular their resolution
over time, three important differences were
noted. First, infants with aberrant PTI had
an earlier onset of symptoms. This was
supported but not explained by the infants
with PIG, all of whom were allocated to the
aberrant PTI group on the basis of both CT
ﬁndings and histology. All four patients with
PIG were symptomatic in the ﬁrst few weeks
of life and underwent lung biopsies at 2 or
3 months of age. After omitting the PIG
cases from the calculations, the onset of
symptoms was still earlier in the aberrant
PTI group (P, 0.0025). Second, infants
with aberrant PTI less frequently had
crackles, a characteristic sign commonly
associated with pneumonia and interstitial
lung disease. Again, in all four subjects with
PIG, no crackles were ever auscultated. Of
interest, more than 86% of the infants with
usual PTI had crackles at diagnosis in
addition to tachypnea, and the triad of
hypoxemia, crackles, and tachypnea was
most characteristic of usual PTI. Third,
failure to thrive at diagnosis was less
common in subjects with aberrant PTI.
This may be explained in part by a
signiﬁcantly shorter period available for
deviation from the growth chart until
symptoms were noted.
Clearly, CT imaging of high quality is
an important tool in the diagnostic workup
of PTI. It is of interest to note that the CT
ﬁndings leading to the aberrant PTI
classiﬁcation were not diffuse or small in
extent and may be secondary to previous
infections or sometimes atelectasis due to
the anesthesiology or sedative procedure.
Thus, CT scans with patterns deviating from
those reported here should point to a need
for further investigations.
Another strength of this study is the
systematic analysis of the lung biopsies. In
comparing the results of three different
immunostaining methods for NECs, we
found that bombesin was the most
informative (Table 3). It showed the
greatest number of immunopositive cells
and was superior to chromogranin and
synaptophysin staining. Only bombesin
staining was signiﬁcantly different between
the control group and the patient groups in
regard to the mean percentage of
bronchioles with at least 10% NECs among
bronchiolar cells. Consistent with the
publication by Young and coworkers, the
control and patient groups showed
immunopositive NECs in more than 70% of
all bronchioles, suggesting that this
criterion may not be speciﬁc for the
diagnosis of NEHI (8).
Our data showed no clinical
differences between two groups of children,
one with and one without biopsies. This
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Figure 3. Frequency distribution of neuroendocrine cells (NECs) as a percentage of total bronchiolar cells in the three study groups (columns) for the three
different stains (rows) applied to consecutive slides. Each bin represents the number of values within a certain range, whereby each bin is labeled with the
midpoint of the bin (e.g., bin 2 = 1.0–2.99). (A) Bombesin stain. (B) Chromogranin stain. (C) Synaptophysin stain. PTI = persistent tachypnea of infancy.
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suggests random sampling of biopsied
cases and a homogeneous underlying
pathophysiology in sampled and
nonsampled cases. For example, biopsies
were done not just in the more severely ill
patients but also depended on the
diagnostic approach of the treating center.
This may compensate for a weakness of our
study (i.e., that we did not have biopsies for
all infants investigated). Of importance,
both groups of infants presented with the
same histopathological pattern, and we did
not ﬁnd an association between the
frequencies of CT abnormalities and
abnormal histopathological ﬁndings
(Fisher’s exact test; data not shown). This
result was expected based on the scattered
distribution of the additional minor CT
ﬁndings, and it was consistent with the
study by Young and colleagues, who
demonstrated no relationship between the
number of NECs and the radiographic
appearance of the region from which the
biopsy specimen was taken (8).
NEC hyperplasia was found in patients
with usual PTI, aberrant PTI, and PIG. Such
NEC hyperplasia is well known in many
other disorders among children with
interstitial lung disease (10). Thus, we can
conclude that lung biopsy does not appear
to be helpful in the diagnosis of PTI when
there is no clinical need to differentiate
the condition further into NEHI or PIG.
On average, the clinical courses were
indistinguishable. However, rarely, PIG can
present as very severe respiratory failure
with pulmonary hypertension and can be
lethal in individual cases (16, 24). Thus, the
deﬁning diagnosis for our series may
encompass less severe PIG cases clinically
indistinguishable from PTI, a potential
selection bias that should be considered.
Symptoms since birth, very severe course,
or CT ﬁndings not ﬁtting usual PTI are red
ﬂags and indicate a need for closer analysis,
including biopsy in individual cases.
Bombesin level in urine did not differ
between control subjects and patients and
was not helpful for diagnosis. This also
suggests that NECs are unlikely to play a
pathogenic role; however, additional
studies are required to analyze more
markers.
Although our study was not focused on
treatment, we made some important
observations in this context. At
presentation, up to 90% of the included
infants had partial respiratory failure with
many desaturations during a day and
transcutaneous oxygen saturation values as
low as 69%. Therefore, many infants received
oxygen supplementation. Age at onset of
oxygen supplementation was somewhat
earlier in aberrant PTI (P = 0.054) (Figure
E1A), which is in agreement with an earlier
start of lung symptoms in this group.
However, ﬂow of oxygen needed and
duration of oxygen therapy were not
different. Oxygen therapy corrected
hypoxemia and, more important, decreased
rates of failure to thrive. Clinical data
showed that both groups of children had a
rather favorable prognosis. Half of the
subjects had fully recovered by age 2.6 years,
and no deaths have been reported so far.
On the basis of the data presented, we
suggest the following diagnostic algorithm.
The diagnosis of PTI can be made by typical
history taking, clinical ﬁndings, and a high-
quality CT scan. Red ﬂags that trigger
further diagnostic measures include a very
early onset (age younger than 4 wk), CT
pattern deviating from the ﬁndings reported
here for usual or aberrant PTI, failure to
thrive despite oxygen therapy, additional
signs or symptoms in other organ systems, a
family history of interstitial lung disease,
and a deteriorating clinical course other
than respiratory tract infections during
long-term follow-up. In the absence of these
red ﬂags, biopsy, lavage, genetic testing, or
other specialized tests are not likely to be
helpful. n
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Table 3. Comparison of Positive Staining for NEC Hyperplasia
NEC Hyperplasia No NEC Hyperplasia
Bombesin, n 18 3
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Aberrant 7 (3 with PIG) 1
Chromogranin, n 8 11*
Usual 5 6
Aberrant 3 5 (3 with PIG)
Synaptophysin, n 7 14*
Usual 3 10
Aberrant 4 (1 with PIG) 4 (2 with PIG)
Definition of abbreviations: NEC = neuroendocrine cell; PIG = pulmonary interstitial glycogenosis.
“NEC hyperplasia” was defined as present when at least 70% of the bronchioles were positive with
NECs and when at least one bronchiole was present with at least 10% NECs.
*P = 0.0014 by Fisher’s exact test. In two subjects, chromogranin stains were missing.
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